Discover
BWAY
BrainsWay Ltd.
15.29
2 x 11.17
2 x 19.58
bid
ask
-
0.22
1.42%
2 @ 04:00 PM
15.29 +0.00 (0.00%)
| Ytd | 60.78% | |
| 1y | 135.59% |
15.06
day range
15.70
5.68
52 week range
17.35
| Open | 15.51 | Prev Close | 15.51 | Low | 15.06 | High | 15.70 | Mkt Cap | 613.58M |
| Vol | 57.67K | Avg Vol | 134.23K | EPS | 0.22 | P/E | 69.50 | Forward P/E | 91.50 |
| Beta | 0.37 | Short Ratio | 0.33 | Inst. Own | 19.22% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 15.37 | 200-d Avg | 11.59 | 1yr Est | 13.72 |
BWAY News
benzinga.com
BrainsWay Presents New Data On Enhancements In Participants With Comorbid Post-Traumatic Stress Diso
BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global le
globenewswire.com
BrainsWay Presents Positive Data from Largest Real-World Study of Deep TMS™ in Patients with Comorbi
Nearly half of individuals diagnosed with PTSD also meet criteria for major depressive disorder (MDD
benzinga.com
BrainsWay Expands Insurance Coverage for Faster Depression Treatment
BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global le
benzinga.com
HC Wainwright & Co. Reiterates Buy on BrainsWay, Maintains $17 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BrainsWay (NASDAQ:BWAY) with a Buy
benzinga.com
BrainsWay Presents New Prospective 12-Month Durability Data Demonstrating Sustained Clinical Benefit
BrainsWay Ltd., a global leader in advanced noninvasive neurostimulation treatments for mental healt